|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013089,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0042679,
umls-concept:C0140080,
umls-concept:C0205195,
umls-concept:C0205314,
umls-concept:C0302350,
umls-concept:C0449445,
umls-concept:C0553580,
umls-concept:C0679622,
umls-concept:C0935989,
umls-concept:C1334088,
umls-concept:C1704259,
umls-concept:C1705987,
umls-concept:C2604851
|
|
pubmed:issue |
11 Pt 1
|
|
pubmed:dateCreated |
2006-6-2
|
|
pubmed:abstractText |
Ewing tumor cell survival and proliferation depends on several autocrine loops. Targeting these loops is a promising therapeutic approach. We recently showed the cytostatic role of imatinib, an inhibitor of the SCF-KIT loop, on Ewing tumor cells, and in this study, we intend to analyze the inhibition of the insulin-like growth factor I receptor (IGF1R) loop.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/MTOR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/NVP ADW742,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, IGF Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/TOR Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/imatinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3532-40
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16740780-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16740780-Apoptosis,
pubmed-meshheading:16740780-Bone Neoplasms,
pubmed-meshheading:16740780-Cell Cycle,
pubmed-meshheading:16740780-Cell Line, Tumor,
pubmed-meshheading:16740780-Cell Proliferation,
pubmed-meshheading:16740780-Dose-Response Relationship, Drug,
pubmed-meshheading:16740780-Down-Regulation,
pubmed-meshheading:16740780-Doxorubicin,
pubmed-meshheading:16740780-Drug Screening Assays, Antitumor,
pubmed-meshheading:16740780-G1 Phase,
pubmed-meshheading:16740780-Humans,
pubmed-meshheading:16740780-Phosphorylation,
pubmed-meshheading:16740780-Piperazines,
pubmed-meshheading:16740780-Protein Kinases,
pubmed-meshheading:16740780-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:16740780-Pyrimidines,
pubmed-meshheading:16740780-Pyrroles,
pubmed-meshheading:16740780-Receptor, IGF Type 1,
pubmed-meshheading:16740780-Sarcoma, Ewing,
pubmed-meshheading:16740780-Structure-Activity Relationship,
pubmed-meshheading:16740780-TOR Serine-Threonine Kinases,
pubmed-meshheading:16740780-Vincristine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
|
|
pubmed:affiliation |
Laboratory 20-Molecular Pathology, Centro de Investigación del Cáncer Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Cientificas, Salamanca, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
